Echinacoside Exerts Antihepatic Fibrosis Effects in High‐Fat Mice Model by Modulating the ACVR2A‐Smad Pathway
Molecular Nutrition & Food Research · 2024-03 · 68 (6)
DOI: 10.1002/mnfr.202300553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, online erschienen am 17.02.2024. Verfasst von Jie Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Linfen Vocational and Technical College, Linfen, Shanxi, 041000, China. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Smad Proteins, Glycosides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Foundation 14th Five-Year Plan of Linfen Vocational and Technical College.
Abstract (Originalsprache)
Scope Nonalcoholic steatohepatitis (NASH) is an increasingly common chronic liver disease in which hepatic fibrosis is the major pathological change. The transforming growth factor β (TGF‐β)/mall mothers against decapentaplegic (Smad) signaling is the main effector of fibrosis. Although the antifibrotic effect of echinacoside (Ech) on the liver has been indicated previously, the cellular and molecular mechanisms remain unclear. This study aims to investigate both in vivo and in vitro antifibrotic properties of Ech. Methods and results Cell viability and scratch/wound assays show that Ech significantly inhibits the proliferation, migration, and activation of human hepatic stellate LX‐2 cells. In mice with high‐fat diet‐induced hepatic fibrosis, Ech treatment attenuates the progression of liver injury, inflammation, and fibrosis. Furthermore, transcriptome analysis and subsequent functional validation demonstrate that Ech achieves antifibrotic effects by the activin receptor type‐2A (ACVR2A)‐mediated TGF‐β1/Smad signaling pathway; ultimately, ACVR2A is demonstrated to be an important target for hepatic fibrosis by inhibiting and inducing the expression of ACVR2A in LX‐2 cells. Conclusion Ech exerts potent antifibrotic effects by inhibiting the ACVR2A‐mediated TGF‐β1/Smad signaling axis and may serve as an alternative treatment for hepatic fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Linfen Vocational and Technical College, Linfen, Shanxi, 041000, China.
- School of Medicine, Shanghai University, Shanghai, 200444, China.
- Medical Security Center, The No. 983th Hospital of Joint Logistics Support Forces of Chinese PLA, Tianjin, 300142, China.
- Department of Pharmacy, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China.
ORCID-Profile: Liyan Xiong
Förderung
- Foundation 14th Five-Year Plan of Linfen Vocational and Technical College
Zitieren
APA
Liang, J., Chen, T., Xu, H., Wang, T., Gong, Q., Li, T., Liu, X., Wang, J., Wang, Y., & Xiong, L. (2024). Echinacoside Exerts Antihepatic Fibrosis Effects in High‐Fat Mice Model by Modulating the ACVR2A‐Smad Pathway. Molecular Nutrition & Food Research, 68(6). https://doi.org/10.1002/mnfr.202300553
Vancouver
Liang J, Chen T, Xu H, Wang T, Gong Q, Li T, et al. Echinacoside Exerts Antihepatic Fibrosis Effects in High‐Fat Mice Model by Modulating the ACVR2A‐Smad Pathway. Molecular Nutrition & Food Research. 2024;68(6). doi:10.1002/mnfr.202300553
BibTeX
@article{Liang2024,
author = {Liang, Jie and Chen, Ting and Xu, Honglei and Wang, Tingfang and Gong, Qi and Li, Tingting and Liu, Xiaoyan and Wang, Jing and Wang, Yun and Xiong, Liyan},
title = {Echinacoside Exerts Antihepatic Fibrosis Effects in High‐Fat Mice Model by Modulating the ACVR2A‐Smad Pathway},
journal = {Molecular Nutrition & Food Research},
year = {2024},
volume = {68},
number = {6},
doi = {10.1002/mnfr.202300553}
}
EUVIMED